Unlock Exceptional Returns: Why Harmony Biosciences is a Top Growth Stock Pick
Investors Seek Growth Stocks Amid Volatility and Risk
Growth investors are constantly on the lookout for stocks that offer above-average growth prospects, but finding such securities is not an easy task. These stocks often come with a higher level of risk, making it essential to be cautious when selecting them. However, by utilizing tools like the Zacks Growth Style Score, investors can better evaluate a company’s true growth potential.
One stock that stands out as a top pick for growth investors is Harmony Biosciences Holdings, Inc. (HRMY). This company has earned a favorable Growth Score and carries a top Zacks Rank, making it an attractive choice for those seeking to capitalize on exceptional returns.
The Importance of Earnings Growth
Earnings growth is arguably the most critical factor in determining a stock’s potential for growth investors. Double-digit earnings growth is often indicative of strong prospects and stock price gains for the company under consideration. For Harmony Biosciences, the historical EPS growth rate is 11.7%, but it’s essential to focus on the projected growth.
The company’s EPS is expected to grow 22.5% this year, significantly surpassing the industry average of 19.1%. This impressive growth rate makes HRMY an attractive choice for investors seeking above-average earnings growth.
Cash Flow Growth and Its Significance
Higher-than-average cash flow growth is more beneficial and important for growth-oriented companies than for mature companies. High cash accumulation enables these companies to undertake new projects without raising expensive outside funds. Currently, year-over-year cash flow growth for Harmony Biosciences is 10%, which is higher than many of its peers.
In fact, the rate compares favorably to the industry average of -4.7%. While investors should consider the current cash flow growth, it’s worth taking a look at the historical rate too for putting the current reading into proper perspective. The company’s annualized cash flow growth rate has been 25.7% over the past 3-5 years versus the industry average of 4.1%.
Promising Earnings Estimate Revisions
The superiority of HRMY in terms of metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is, of course, favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
The current-year earnings estimates for Harmony Biosciences have been revising upward. The Zacks Consensus Estimate for the current year has surged 0.2% over the past month. This positive trend in earnings estimate revisions further supports HRMY’s potential as a top growth pick.
Harmony Biosciences: A Solid Choice for Growth Investors
In conclusion, Harmony Biosciences Holdings, Inc. (HRMY) is an attractive choice for growth investors due to its favorable Growth Score and top Zacks Rank. The company’s impressive earnings growth rate, higher-than-average cash flow growth, and positive trend in earnings estimate revisions make it a solid pick.
By utilizing the Zacks Growth Style Score and other tools, investors can better evaluate a company’s true growth potential and make more informed investment decisions. Whether you’re a seasoned investor or just starting out, Harmony Biosciences is definitely worth considering as part of your portfolio.
Conclusion
Investors seeking above-average growth prospects should consider using the Zacks Growth Style Score to evaluate companies like Harmony Biosciences Holdings, Inc. (HRMY). With its favorable Growth Score and top Zacks Rank, HRMY presents an attractive opportunity for growth investors looking to capitalize on exceptional returns.
By understanding the importance of earnings growth, cash flow growth, and earnings estimate revisions, investors can make more informed decisions about which stocks to choose. Whether you’re a seasoned investor or just starting out, Harmony Biosciences is definitely worth considering as part of your portfolio.
